A Phase II Trial of Letrozole Plus OSI-774 (Tarceva) in Post-menopausal Women With ER and/or PR-Positive Metastatic Breast Cancer.

Trial Profile

A Phase II Trial of Letrozole Plus OSI-774 (Tarceva) in Post-menopausal Women With ER and/or PR-Positive Metastatic Breast Cancer.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 12 Jul 2012

At a glance

  • Drugs Erlotinib; Letrozole
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Jul 2012 Actual end date Dec 2008 added as reported by ClinicalTrials.gov.
    • 12 Jul 2012 Actual end date Dec 2008 added as reported by ClinicalTrials.gov.
    • 12 Jul 2012 Actual patient number changed from 49 to 48 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top